Aegis Capital Starts Can-Fite BioPharma (CANF) at Buy
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Aegis Capital analyst Christian Anketell initiates coverage on Can-Fite BioPharma (NYSE: CANF) with a Buy rating and a price target of $5.00.
Analyst comments: "
We expect several catalysts to drive the stock over the next 12 months which include 1.) the top-line results in 4Q 2021 from the ongoing Phase III study for Piclidenoson for psoriasis; 2.) the advancement of Namodenoson to Phase III clinical trial by end of 2021 for liver cancer treatment; 3.) the expansion of these drug treatments to other indications; 4.) continuing to sign exclusive distribution agreements, 5.) advancing through the cannabinoid program."
Shares of Can-Fite BioPharma closed at $2.20 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Morgan Stanley Upgrades Sony Corp. (6758:JP) (SNE) to Overweight
- Entegris Inc (ENTG) PT Raised to $131 at Stifel
- FANUC Corp (6954:JP) (FANUY) PT Raised to JPY25,000 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!